Jefferies Rates ABIVAX Société Anonyme (ABVX) buy

Jefferies analyst Faisal Khurshid raised the firm's rating on ABIVAX Société Anonyme to buy on June 30, 2026, with a $158 price target, a 17.52% upside from the current price.

By TradeTexts Research Desk · Published Jun 30, 2026, 9:05 PM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Jefferies rated ABIVAX Société Anonyme ($ABVX) "buy" with a $158 price target on June 30, 2026.

Since the rating, $ABVX is up 6.7% after 1 week, down 6.7% after 1 month and down 33.9% to date (from the $133.26 close on Jun 30, 2026).

ABVX ABIVAX Société Anonyme

$88.13 -34.12% year to date

Daily close · Oct 16, 2026

Key Points

Jefferies raised its rating on ABIVAX Société Anonyme to buy on June 30, 2026, setting a price target of $158.
Jefferies's $158 price target implies 17.52% upside from ABIVAX Société Anonyme's ($ABVX) current $134.44 share price.
ABIVAX Société Anonyme shares trade around $134.44, sitting well above their 50-day moving average of $108.41.
Wall Street maintains an overall strong buy consensus on the clinical-stage biotech firm with a mean target price of $163.58 across 12 analyst opinions.

Get $ABVX trade alerts by text

We text you when insiders, Congress or big funds trade $ABVX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated ABIVAX Société Anonyme alert may contain errors. Disclosures

Jefferies Moves on ABIVAX Société Anonyme ABVX Stock

Jefferies analyst Faisal Khurshid raised the firm's rating on ABIVAX Société Anonyme (NasdaqGM: ABVX) to buy on June 30, 2026, establishing a price target of $158. The upgrade places fresh attention on the clinical-stage biotechnology company as Wall Street evaluates its developmental pipeline in chronic inflammatory diseases.

Analyst rating track record

Jefferies vs. the S&P 500

YTD return +49.26% hypothetical

All-time return +129% S&P 500 +28.13%

vs. S&P 500 +100.87% ahead of the index

Hypothetical returns from Jefferies's disclosed trades, not real profit or advice. How we model this.

12-month forecast

$ABVX price target

ABIVAX Société Anonyme daily closes and this analyst's $158 target. Not advice.

ABIVAX Société Anonyme ABVX Stock Trades Near Midpoint of 52-Week Range

ABIVAX Société Anonyme ABVX shares traded at $134.44 recently, comfortably above their 50-day moving average of $108.41 and their 200-day moving average of $116.29. The stock has experienced a wide trading window over the past year, falling as low as $69.81 and reaching a high of $148.83. With a market capitalization of roughly $8.06 billion, the stock remains active among healthcare investors tracking clinical trial updates for its lead drug candidate, obefazimod.

Wall Street Analyst Coverage and Consensus

Other major brokerage firms have also updated their outlooks on ABIVAX Société Anonyme ABVX recently. On September 22, 2026, Truist Securities maintained its buy rating while adjusting its price target to $151 from $155, and Wedbush maintained a neutral rating with a price target lowered to $118 from $140. On the same day, Barclays kept its overweight rating at a $148 target. Earlier in the autumn, Goldman Sachs initiated coverage with a buy rating and a $155 price target on September 10, 2026, while BTIG reiterated a buy rating with a $175 target on September 5, 2026. Piper Sandler previously maintained an overweight rating on July 9, 2026, raising its target to $175 from $165, and Truist Securities had earlier maintained a buy rating with a $155 target on July 2, 2026, following Citizens reiterating a market outperform rating with a $187 target on July 1, 2026. Across 12 analyst opinions, the stock carries a consensus recommendation key of strong buy, with a mean price target of $163.58, a high target of $181, and a low target of $142.

Inside ABIVAX Société Anonyme Operations

Headquartered in Paris, France, ABIVAX Société Anonyme focuses on developing therapeutics that help stabilize the immune response for patients suffering from chronic inflammatory diseases. Its primary candidate, obefazimod, is advancing through Phase 3 clinical development for moderately to severely active ulcerative colitis, alongside Phase 2b clinical trials for Crohn's disease. The company operates with a lean team of 98 employees.

What to Watch Next for ABIVAX Société Anonyme ABVX

Investors will look toward upcoming clinical milestones and future earnings reports to gauge the progress of obefazimod through its late-stage trials. The company's next corporate earnings update is expected around March 22, 2027.